Last reviewed 2026-04-20 · How we verify

Lidocaine 10%

Lidocaine 10%, marketed by University Hospital, Basel, Switzerland, is a well-established anesthetic with a strong presence in the healthcare sector. The key composition patent is set to expire in 2028, providing a significant period of market exclusivity and potential revenue stability. However, the lack of reported primary trial results and revenue data poses a risk in assessing its ongoing competitiveness and market impact.

At a glance

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

• Effect of Lidocaine Infusion Versus Dexmedemidine Infusion on the Neurocognitive Function of Elderly Patients Undergoing Endoscopic Retrograde Cholangiopancreatography(ERCP): a Randomized, Controlled Trial. (NA)
• Long-term Outcomes of Lidocaine Infusions for Post-Operative Pain (LOLIPOP) Trial (PHASE3)
• USG-Guided Shoulder Injections in Frozen Shoulder (NA)
• Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments (PHASE2)
• Efficacy and Safety of Combined Nanofat Injection With Either Platelet Rich Fibrin or Microneedling Versus Nanofat Injection Alone in the Treatment of Facial Atrophic Post Acne Scars (NA)
• Using Lidocaine or Dexmedetomidine to Help Control Blood Pressure Spikes From a Tourniquet During Knee Surgery (PHASE2)
• Efficacy of Autologous Conditioned Serum in Temporomandibular Joint Disorder (NA)
• Ketamine-lidocaine Versus Ketamine-fentanyl for Induction of Anesthesia in Patients With Left Ventricular Systolic Dysfunction Undergoing Elective Coronary Artery Bypass (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.